StreetInsider.com News Articles

Form 10-K ORASURE TECHNOLOGIES For: Dec 31

Mon, 09 Mar 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260309/26132580.html

Form 10-K ORASURE TECHNOLOGIES For: Dec 31

Mon, 09 Mar 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260309/26132580.html

Form 8-K ORASURE TECHNOLOGIES For: Feb 28

Thu, 05 Mar 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260305/26119141.html

Form 8-K ORASURE TECHNOLOGIES For: Feb 28

Thu, 05 Mar 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260305/26119141.html

Form 4 ORASURE TECHNOLOGIES For: Mar 01 Filed by: McGrath Kenneth J

Tue, 03 Mar 2026 21:12:00 -0400

si-local-file:///var/storage/secattach/20260303/26105555.html

Form 4 ORASURE TECHNOLOGIES For: Mar 01 Filed by: McGrath Kenneth J

Tue, 03 Mar 2026 21:12:00 -0400

si-local-file:///var/storage/secattach/20260303/26105555.html

Form 4 ORASURE TECHNOLOGIES For: Mar 01 Filed by: EGLINTON MANNER CARRIE

Tue, 03 Mar 2026 21:11:00 -0400

si-local-file:///var/storage/secattach/20260303/26105549.html

Form 4 ORASURE TECHNOLOGIES For: Mar 01 Filed by: EGLINTON MANNER CARRIE

Tue, 03 Mar 2026 21:11:00 -0400

si-local-file:///var/storage/secattach/20260303/26105549.html

OraSure Technologies (OSUR) Reports In-Line Q4 EPS

Wed, 25 Feb 2026 17:51:51 -0400

OraSure Technologies (NASDAQ: OSUR) reported Q4 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $26.76 million versus the consensus estimate of $28.08 million.

For earnings history and earnings-related data on OraSure Technologies (OSUR) click here.

Form 8-K ORASURE TECHNOLOGIES For: Feb 25

Wed, 25 Feb 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260225/26060085.html

Form 8-K ORASURE TECHNOLOGIES For: Feb 25

Wed, 25 Feb 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260225/26060085.html

OraSure Announces Fourth Quarter 2025 Financial Results

Wed, 25 Feb 2026 16:05:00 -0400

BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2025.

“Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range,” said Carrie Eglinton Manner, President and CEO of OTI. “We supported our customers in navigating a challenging funding environment in 2025, and we are encouraged to see increasing signs of stability in key segments as we

OraSure Announces Fourth Quarter 2025 Financial Results

Wed, 25 Feb 2026 16:05:00 -0400

Form SCHEDULE 13G/A ORASURE TECHNOLOGIES Filed by: GAGNON SECURITIES LLC

Thu, 12 Feb 2026 17:56:00 -0400

si-local-file:///var/storage/secattach/20260212/25993658.html

Form SCHEDULE 13G/A ORASURE TECHNOLOGIES Filed by: GAGNON SECURITIES LLC

Thu, 12 Feb 2026 17:56:00 -0400

si-local-file:///var/storage/secattach/20260212/25993658.html

OraSure receives Health Canada license for HIV self-test

Tue, 10 Feb 2026 08:05:42 -0400

OraSure Technologies (NASDAQ: OSUR) announced that Health Canada has licensed its OraQuick HIV Self-Test for use in Canada. The oral fluid test represents the first HIV self-test of its kind approved for Canadian consumers.

The test detects antibodies for HIV-1 and HIV-2 using a simple oral swab and provides results in 20 minutes. Users can conduct the test at home, pharmacies, or community testing events. The product has been available in the United States since 2012 and is sold in more than 60 countries.

According to the Public Health Agency of Canada, there were 1,826 new HIV diagnoses in 2024, excluding Quebec,

OraSure to Launch OraQuick™ HIV Self-Test in Canada

Tue, 10 Feb 2026 08:05:00 -0400

BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada.

The OraQuick™ HIV Self-Test is a point-of-care rapid antibody test. It is Canada’s first oral HIV self-test and detects antibodies for both HIV-1 and HIV-2, enabling individuals to find out their HIV status with a simple oral swab in as little as 20 minutes. The simplicity of the product makes it ideal for testing

OraSure to Launch OraQuick™ HIV Self-Test in Canada

Tue, 10 Feb 2026 08:05:00 -0400

OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

Mon, 09 Feb 2026 16:15:00 -0400

BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026.

A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has

OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

Mon, 09 Feb 2026 16:15:00 -0400

Form DEFA14A ORASURE TECHNOLOGIES

Thu, 15 Jan 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20260115/25855171.html

Form DEFA14A ORASURE TECHNOLOGIES

Thu, 15 Jan 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20260115/25855171.html

OraSure Technologies receives director nominations from Altai Capital

Thu, 15 Jan 2026 13:00:34 -0400

OraSure Technologies Inc. (NASDAQ: OSUR) confirmed that Altai Capital has nominated two candidates, including fund founder Rishi Bajaj, for election to the company's board of directors at its 2026 annual meeting of stockholders.

The board had previously interviewed Bajaj for potential service but ultimately decided to appoint an alternative candidate as director. OraSure stated that Altai has not accepted the board's subsequent offers to make certain directors available for further engagement.

OraSure's board has undergone significant changes since 2022, with seven directors departing and three new independent directors joining. The company added healthcare investor Steven K. Boyd in October 2025 and appointed

OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital

Thu, 15 Jan 2026 13:00:00 -0400

BETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has nominated two candidates, including the fund’s founder Rishi Bajaj, to stand for election to the Company’s Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.

As previously announced, OraSure’s Board has engaged extensively with Altai Capital. The Board interviewed Mr. Bajaj for potential service on the Board and ultimately decided to appoint an alternative candidate to serve

OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital

Thu, 15 Jan 2026 13:00:00 -0400